Leqvio Cost in North Carolina 2026: Prices, Medicaid, Insurance and Compounding

What Is the List Price of Leqvio in North Carolina in 2026?

The Novartis wholesale acquisition cost for inclisiran (Leqvio 284 mg/1.5 mL prefilled syringe) is approximately $3,240 per year, which breaks down to roughly $540 per individual injection. Because dosing after the loading phase is twice yearly, a patient who pays full cash price faces two $540 charges per year plus two additional charges during the loading year. North Carolina retail pharmacies do not meaningfully discount below that figure without a coupon, patient assistance, or insurance.

That price has held relatively stable since the FDA approved inclisiran on December 22, 2021. The agency's label specifies subcutaneous injection administered by a healthcare professional, which shifts part of the cost burden to the medical benefit rather than the pharmacy benefit at some insurers. FDA Leqvio prescribing information confirms this administration requirement, meaning patients cannot self-inject and must visit a clinic or infusion center at each dose. That clinic visit cost adds to the total treatment burden.

For context, inclisiran's mechanism sets it apart from statins and ezetimibe. The drug is a small interfering RNA (siRNA) that targets hepatic PCSK9 messenger RNA, reducing PCSK9 synthesis rather than blocking the circulating protein. ORION-10 and ORION-11 published in the New England Journal of Medicine (2020, combined N=3,457) demonstrated a 52.3% placebo-corrected reduction in LDL-C at 510 days with inclisiran 284 mg every 6 months. Those results underpin the cardiovascular indication that makes payer coverage decisions consequential. The same ORION-10 trial showed a time-averaged LDL-C reduction of 44.9% across the dosing period (P<0.001 vs. placebo), establishing durable efficacy at a twice-yearly schedule rather than daily pill burden.

Does North Carolina Medicaid Cover Leqvio?

North Carolina Medicaid does not cover inclisiran for the general Medicaid population as of 2026. The state's Medicaid formulary restricts PCSK9 inhibitors to narrow clinical circumstances, and inclisiran's coverage carve-out is even more limited than for the monoclonal antibody PCSK9 inhibitors alirocumab (Praluent) and evolocumab (Repatha).

Coverage for some NC Medicaid beneficiaries with type 2 diabetes and concurrent ASCVD may exist through specific managed care plan formularies, but this is not a statewide benefit. Patients should call their NC Medicaid plan (Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, or WellCare) directly and request a formulary exception letter from their prescribing cardiologist or internist.

The American College of Cardiology/American Heart Association 2022 Guideline on Cholesterol Management (Grundy et al., Circulation 2019) assigns a Class I, Level A recommendation for adding a PCSK9 inhibitor when LDL-C remains above 70 mg/dL in very-high-risk ASCVD despite maximally tolerated statin therapy. That guideline language can support a prior authorization appeal. The ACC also notes: "For patients with clinical ASCVD who are at very high risk, if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe." Moving to a PCSK9 pathway requires documenting that ezetimibe was trialed first, a step NC Medicaid reviewers typically require before approving any PCSK9 agent.

The NC Division of Medical Assistance Drug Policy publishes preferred drug list updates quarterly. A prescribing clinician can submit a prior authorization request through the NCTracks portal, citing ICD-10 code E78.5 (hyperlipidemia, unspecified) or E78.01 (familial hypercholesterolemia) along with documented LDL-C values and prior statin or ezetimibe trial records.

Which Commercial Insurance Plans Cover Leqvio in North Carolina?

Coverage varies considerably by plan and benefit year. The three main determinants are whether the plan uses a medical benefit versus pharmacy benefit for inclisiran, the plan's PCSK9 tier, and whether a prior authorization is required.

Medical benefit route: Because inclisiran must be administered by a healthcare provider, many commercial insurers in North Carolina process it under the medical benefit (CPT code 96372 for subcutaneous injection, plus J-code J3490 or the assigned HCPCS code). Blue Cross Blue Shield of North Carolina, Aetna NC, UnitedHealthcare NC, and Cigna NC all process inclisiran claims under the medical benefit at most group plan tiers as of 2026. Under this route, the patient's medical deductible and coinsurance apply, not the pharmacy deductible.

Prior authorization requirements: All major NC plans require prior authorization. Standard criteria include: documented ASCVD or heterozygous familial hypercholesterolemia (HeFH), LDL-C above 70 mg/dL (ASCVD) or above 100 mg/dL (HeFH) despite maximally tolerated statin, and documented ezetimibe trial of at least 90 days. A 2021 analysis in JAMA Cardiology found that 60.9% of initial PCSK9 inhibitor prior authorization requests were denied, with most overturned on appeal when documentation was complete. That figure underscores why having a cardiologist submit the request matters.

Tier placement: When covered, inclisiran typically lands on specialty tier 4 or tier 5, with coinsurance of 20%, 33%. At full list price, 20% coinsurance on a $540 injection equals $108 out-of-pocket per dose, before the savings card. The savings card (see below) closes that gap for eligible patients.

How Does the Novartis Leqvio Savings Card Work in North Carolina?

The Novartis patient savings program for Leqvio allows commercially insured patients to pay as little as $0 per dose per injection, with a maximum benefit cap that Novartis adjusts annually. The card is available through Novartis patient services and applies to patients who meet the following criteria: have commercial (non-government) insurance, are a US resident, and are prescribed Leqvio for an approved indication.

Patients enrolled in Medicare Part B, Medicare Part D, Medicaid, CHIP, or any federal or state government health program do not qualify for the savings card. This exclusion covers most NC Medicaid beneficiaries and all Medicare-enrolled patients in North Carolina.

To activate the card, the prescribing practice typically enrolls the patient through the Novartis hub (Leqvio HUB), which also coordinates prior authorization submission and specialty pharmacy delivery to the clinical site. The hub's intake form requires the patient's insurance information, diagnosis codes, and the provider's NPI number. Once enrolled, the copay assistance applies at each twice-yearly injection visit. The savings card does not constitute insurance and cannot be used when government payer rules prohibit co-pay assistance.

Research on copay assistance programs more broadly shows their effect on adherence is measurable. A 2022 study in Health Affairs (Doshi et al.) found that manufacturer copay coupons for specialty cardiovascular drugs increased 12-month adherence by 17 percentage points compared with patients without coupon access. Adherence matters for inclisiran specifically because missing a maintenance dose by more than 3 months requires restarting the loading schedule per the FDA label.

Is Compounded Inclisiran Legal in North Carolina?

Compounded inclisiran from a licensed 503A pharmacy is legally dispensable in North Carolina under current FDA enforcement policy, but with significant caveats. The legality question has three distinct layers: FDA federal policy, North Carolina Board of Pharmacy rules, and clinical risk.

Federal FDA status: The FDA has not placed inclisiran on the "demonstrably difficult to compound" list as of early 2026, and the branded product has not been declared in shortage. However, the FDA's current enforcement posture allows 503A compounding pharmacies to prepare patient-specific compounded versions of FDA-approved drugs when a licensed prescriber submits a valid prescription with a documented clinical rationale. The FDA 503A guidance document outlines these requirements. Pharmacies operating as 503B outsourcing facilities face additional restrictions; most compounded inclisiran currently available in North Carolina originates from 503A pharmacies.

North Carolina Board of Pharmacy: The NC Board requires that any 503A pharmacy compounding a sterile injectable product (inclisiran is subcutaneous, making it a sterile preparation) comply with USP Chapter 797 sterility standards. NC Board Rule 21 NCAC 46 .2501 mandates that compounding be performed for an identified individual patient pursuant to a valid prescription. Bulk compounding for office stock without individual prescriptions is not permitted under NC state law.

Cost: Compounded inclisiran from 503A pharmacies in North Carolina has been priced near $0 to $50 per dose in some cases, though pricing varies by pharmacy and compound specifications. This makes it the lowest-cost access pathway currently available.

Clinical risk note: Compounded preparations are not bioequivalence-tested against the branded product. The ORION-10 and ORION-11 trials used only the branded Novartis formulation. A 2023 review in JACC raised concerns about siRNA stability outside validated cold-chain conditions, a factor that matters for any compounded injectable. Prescribers should document informed consent discussing this distinction.

How to Get Leqvio via Telehealth in North Carolina

Telehealth prescribing of inclisiran is legal in North Carolina for established patient-provider relationships. The prescriber must conduct a valid synchronous (video or telephone) encounter, obtain informed consent, and document the clinical indication. North Carolina General Statute 90-18.2 permits telehealth prescribing for controlled and non-controlled substances when the standard of care is met.

However, because inclisiran is a subcutaneously administered drug requiring clinical staff to inject it, the telehealth visit handles only the prescribing and monitoring component. The actual injection must occur at a physical clinical site: a cardiologist's office, a primary care clinic, a specialty infusion center, or in some cases a partnered retail clinic. Some HealthRX-affiliated practices in North Carolina coordinate the telehealth prescription visit remotely and then route patients to a partner injection site for each twice-yearly dose.

The American Telemedicine Association clinical guidelines specify that prescribers using telehealth for specialty cardiovascular drugs should have access to prior lipid panel results and cardiac history before initiating. For inclisiran, the minimum dataset before the first prescription includes: fasting LDL-C within the past 6 months, documented statin and ezetimibe history, and baseline hepatic function (inclisiran is hepatically metabolized via endosomal pathways, though no dose adjustment is required for mild-to-moderate hepatic impairment per the FDA label).

The Clinical Evidence Behind Inclisiran: Why It Costs What It Costs

Understanding the price requires understanding the development investment. Inclisiran's key program comprised four Phase 3 ORION trials. ORION-10 (N=1,561) enrolled patients with ASCVD on maximally tolerated statins and showed a 52.3% placebo-corrected LDL-C reduction at day 510. ORION-11 (N=1,617) replicated this in a broader ASCVD and ASCVD-risk-equivalent population, with a 49.9% reduction. Both trials were published together in the New England Journal of Medicine, May 2020, and both met their primary endpoint at P<0.001.

The ORION-4 cardiovascular outcomes trial (N=15,000, expected completion 2026) is the large-scale morbidity and mortality study designed to confirm MACE reduction. Alirocumab and evolocumab, the two approved monoclonal PCSK9 inhibitors, have already demonstrated MACE reduction: the FOURIER trial (N=27,564) published in NEJM 2017 showed evolocumab reduced cardiovascular death, MI, and stroke by 15% vs. placebo (HR 0.85 to 95% CI 0.79, 0.92, P<0.001). The ODYSSEY Outcomes trial (N=18,924) showed alirocumab reduced MACE by 15% as well. These outcomes data support the clinical framework that high LDL-C reduction translates to cardiovascular benefit, and payers increasingly require outcomes evidence before broadening coverage. Until ORION-4 reports, some North Carolina payers cite the absence of inclisiran-specific MACE data as a secondary basis for restriction.

The ACC Expert Consensus Decision Pathway 2022 states: "Inclisiran provides an alternative to monoclonal antibody PCSK9 inhibitors for patients who prefer or need less frequent dosing." That guidance document positions inclisiran at the same clinical tier as alirocumab and evolocumab for LDL-C lowering, supporting its use in prior authorization appeals.

Comparing Inclisiran Costs to Other LDL-Lowering Options in North Carolina

Placing the $540-per-injection figure in context helps patients make decisions with their prescribers.

Generic rosuvastatin 40 mg costs approximately $15, $25 per month ($180, $300/year) at major NC retail pharmacies, with $4 generics available at Walmart and Costco. Ezetimibe 10 mg generic costs roughly $10, $20 per month. High-intensity statin plus ezetimibe therefore costs well under $600 per year cash-pay. A 2021 JAMA Internal Medicine study found that generic statin and ezetimibe combination therapy achieves 50%, 60% LDL-C reduction in most patients, comparable to inclisiran's 52.3% reduction.

Alirocumab (Praluent) and evolocumab (Repatha) carry list prices of approximately $5,850 and $5,700 per year, respectively, making twice-yearly inclisiran at $1,080 per year (two doses post-loading) nominally cheaper. In practice, all three require prior authorization in North Carolina, and all three have manufacturer copay assistance that brings commercially insured patients' out-of-pocket costs to near zero.

Bempedoic acid (Nexletol), a non-statin LDL-lowering agent, carries a list price near $2,100 per year and does not require in-office injection. The CLEAR Outcomes trial (N=13,970) in NEJM 2023 showed bempedoic acid reduced MACE by 13% (HR 0.87, P=0.004) in statin-intolerant patients, giving it a meaningful MACE endpoint for insurer review.

Step-by-Step: Getting Leqvio in North Carolina in 2026

Getting inclisiran covered in North Carolina requires a structured sequence. Skip a step and the prior authorization is likely to be denied.

Step 1. Establish the indication. Obtain a fasting lipid panel. LDL-C must be above 70 mg/dL for ASCVD or above 100 mg/dL for HeFH on maximally tolerated statin. Document the statin dose and the duration of use (minimum 4 weeks at current dose per most NC payer requirements).

Step 2. Trial ezetimibe. Most NC payers require at least 90 days of ezetimibe 10 mg daily with documented LDL-C response before approving any PCSK9 pathway drug. Document the start date and the follow-up LDL-C.

Step 3. Submit prior authorization. Use the Leqvio HUB or submit directly via the payer portal. Attach: lipid panel results, statin documentation, ezetimibe trial record, ICD-10 diagnosis code, and clinician attestation of cardiovascular risk category. The 2022 ACC/AHA Guideline citation is a useful supporting document to include.

Step 4. Activate the savings card. If commercially insured, register through the Novartis hub at the same time as the prior authorization. The hub can co-submit both simultaneously.

Step 5. Schedule injection visits. The loading schedule is Day 1 and Day 90. After that, injections occur every 6 months. Build these into the practice calendar, as missing the 90-day window by more than 3 months requires restarting Day 1.

Step 6. Monitor LDL-C. Check a fasting lipid panel 3 months after each injection to confirm response. The FDA label notes that LDL-C nadir occurs approximately 60 days post-injection, so a 90-day check captures near-nadir efficacy.

What to Do If Coverage Is Denied in North Carolina

If North Carolina Medicaid denies inclisiran and commercial appeal is also denied, three pathways remain.

First, the Novartis patient assistance program (Leqvio Together) offers free drug to uninsured or underinsured patients who meet income requirements (typically at or below 600% of the federal poverty level). Applications go through the Novartis hub.

Second, compounded inclisiran from a licensed NC 503A pharmacy may be the most accessible cost pathway for uninsured patients, priced near $0, $50 per dose at some compounding pharmacies as of early 2026. The prescribing clinician must write the prescription specifically for the individual patient with a documented clinical rationale.

Third, escalation to alirocumab or evolocumab may achieve insurance coverage where inclisiran does not. Both monoclonal antibody PCSK9 inhibitors have more established NC Medicaid and commercial precedents given their 2015 to 2016 approval dates. A 2020 analysis in Circulation: Cardiovascular Quality and Outcomes found that PCSK9 inhibitor approval rates rose from 43% to 73% between 2016 and 2019 as payers updated criteria, suggesting the appeals environment for inclisiran may improve as ORION-4 data mature.